Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear

Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic…

Read More

AI’s Healthcare ‘Doomsday’? It May Be Less About Autonomy Than Trust

For one ICU physician and startup CMO, the more immediate danger isn’t an autonomous system taking over medicine and leaving human decision-making behind. It’s healthcare organizations harnessing AI primarily to increase efficiency while leaving healthcare providers even more mired in complexity and regulation. The post AI’s Healthcare ‘Doomsday’? It May Be Less About Autonomy Than…

Read More